Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy

Completed · Phase 1/Phase 2

Conditions studied: Psoriasis

In brief

To evaluate whether a short-term course of methotrexate in patients treated with efalizumab (Raptiva) increases efficacy. The secondary objectives of this study are 1) to evaluate the efficacy of Raptiva in maintaining the clinical improvement induced by short-term treatment with combination therapy of Raptiva and methotrexate 2) to evaluate the safety of short-term combination therapy of Raptiva and methotrexate.

Key facts

Study ID

NCT00368654

Run by

University of California, Davis

People needed

12

Starts

2007-01-01

Expected to finish

2008-05-01

Last updated by the study team

2018-06-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Moderate to severe plaque-type psoriasis
• A candidate for systemic therapy or phototherapy
• Not using prescription systemic therapies for psoriasis prior to starting the study
• Not using efalizumab within 3 months prior to starting the study
• We are seeking adults who:
• Have moderate to severe plaque-type psoriasis
• Are generally healthy
• Are not hypersensitive to Raptiva® (efalizumab) or any of its components.
• Are not pregnant or lactating women
• You will:
• Be interviewed and examined
• Have blood drawn
• Be injecting the study medication

You may not qualify if…

• Hypersensitivity to Raptiva or any of its components
• Pregnant or lactating women
• History of liver disease or abnormal liver enzymes
• History of chronic infection or malignancy
• History of significant hematologic abnormalities

Where it is running

• University of California, Davis Medical Center Department of Dermatology — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.